Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trametinib + dabrafenib
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
trametinib + dabrafenib is a combination therapy being investigated by the Universitair Ziekenhuis Brussel in the TraMel-WT (NCT04059224) phase 2 clinical trial for the treatment of advanced BRAF V600 wild-type melanoma. The regimen consists of a standard dose of the MEK inhibitor trametinib (2 mg once daily) and a low dose of the BRAF inhibitor dabrafenib (50 mg twice daily). In this specific clinical context, trametinib serves as the primary therapeutic agent by inhibiting MEK1 and MEK2 kinases within the MAPK signaling pathway to suppress tumor growth. The low-dose dabrafenib is added not for its anti-tumor activity—as the patients have BRAF wild-type tumors—but specifically to mitigate trametinib-related skin toxicities, such as acneiform rash, by modulating paradoxical MAPK pathway activation in keratinocytes.
- Brand names
- MekinistTafinlar
- Other names
- trametinib and low-dose dabrafenib
02
Targets
MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)BRAF (B-Raf proto-oncogene, serine/threonine kinase)
Beyond the preview
Go deeper on trametinib + dabrafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trametinib + dabrafenib.